Alessandra Fusco et al. 2017. Short-term Cardio-Vascular Risk Score Changes in Type 2 Diabetic Patients on Empaglifozin: A Real-Life Clinical Experience. Heart Research. 4, 3 (Jul. 2017), 46–56. DOI:https://doi.org/10.17140/HROJ-4-141.